Brief: Delaware District Court Rules In Favor Of Acadia In Nuplazid Formulation Patent Litigation
16/05/2025 18:45
May 16 (Reuters) - ACADIA Pharmaceuticals Inc ACAD.O: DELAWARE DISTRICT COURT RULES IN FAVOR OF ACADIA IN NUPLAZID® (PIMAVANSERIN) FORMULATION PATENT LITIGATION ACADIA PHARMACEUTICALS INC - COURT UPHOLDS ACADIA'S '721 FORMULATION PATENT FOR NUPLAZID Source text: ID:nBwk22TBa Further company coverage: ACAD.O ((Reuters.Briefs@thomsonreuters.com;))
Recent news on Acadia Pharmaceuticals
See all newsU.S. STOCKS ON THE MOVE-FactSet, Moderna, Goldman Sachs
U.S. STOCKS ON THE MOVE-Biogen, Incyte, Quantum Cyber
U.S. STOCKS ON THE MOVE-Fortrea, Nuvation Bio, Acadia Pharmaceuticals
Acadia Pharma jumps after EU panel reverses opinion on neurological disorder drug
Brief: Daybu® (Trofinetide) Recommended For Approval In The European Union By CHMP